PubRank

Luciano Burattini

Author PubWeight™ 16.07‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol 2006 1.45
2 Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2013 1.08
3 High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol 2014 1.05
4 Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. Int J Cancer 2013 1.01
5 Progress of molecular targeted therapies for advanced renal cell carcinoma. Biomed Res Int 2013 1.00
6 Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. Int J Cancer 2013 0.89
7 Essential role of Gli proteins in glioblastoma multiforme. Curr Protein Pept Sci 2013 0.89
8 Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder. Adv Urol 2012 0.89
9 Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol 2014 0.89
10 Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming? Curr Cancer Drug Targets 2013 0.87
11 Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. Future Oncol 2014 0.85
12 Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. Oncology 2006 0.83
13 Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity. Recent Pat Antiinfect Drug Discov 2012 0.80
14 Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. J Neurooncol 2013 0.80
15 Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer Metastasis Rev 2014 0.78
16 VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. Anticancer Res 2013 0.76
17 Short communication: the efficacy of fixed dose rate infusion of gemcitabine combined with IFN-alpha2a in patients with advanced refractory renal cell carcinoma. J Interferon Cytokine Res 2005 0.76
18 Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. Oncol Lett 2012 0.75
19 Angiogenetic pathway as a therapeutic target in renal cell carcinoma. Anal Quant Cytol Histol 2012 0.75